Cargando…
Recombinant BCG expressing the LTAK63 adjuvant improves a short-term chemotherapy schedule in the control of tuberculosis in mice
Tuberculosis (TB) is one of the deadliest infectious diseases around the world. Prevention is based on the prophylactic use of BCG vaccine, effective in infants but as protection wanes with time, adults are less protected. Additionally, chemotherapy requires the use of many antibiotics for several m...
Autores principales: | Trentini, Monalisa Martins, Kanno, Alex Issamu, Rodriguez, Dunia, Marques-Neto, Lazaro Moreira, Eto, Silas Fernandes, Chudzinki-Tavassi, Ana Marisa, Leite, Luciana Cezar de Cerqueira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471321/ https://www.ncbi.nlm.nih.gov/pubmed/36119106 http://dx.doi.org/10.3389/fimmu.2022.943558 |
Ejemplares similares
-
CRISPR/Cas9 Approach to Generate an Auxotrophic BCG Strain for Unmarked Expression of LTAK63 Adjuvant: A Tuberculosis Vaccine Candidate
por: Moraes, Luana, et al.
Publicado: (2022) -
Recombinant BCG expressing the LTAK63 adjuvant increased memory T cells and induced long-lasting protection against Mycobacterium tuberculosis challenge in mice
por: Marques-Neto, Lázaro Moreira, et al.
Publicado: (2023) -
Recombinant BCG expressing the LTAK63 adjuvant induces increased early and long-term immune responses against Mycobacteria
por: Carvalho Dos Santos, Carina, et al.
Publicado: (2019) -
Recombinant BCG Expressing LTAK63 Adjuvant induces Superior Protection against Mycobacterium tuberculosis
por: Nascimento, Ivan P., et al.
Publicado: (2017) -
Recombinant BCG-LTAK63 Vaccine Candidate for Tuberculosis Induces an Inflammatory Profile in Human Macrophages
por: dos Santos, Carina C., et al.
Publicado: (2022)